Last reviewed · How we verify
Folferi and celecoxib
FOLFIRI chemotherapy combined with celecoxib inhibits tumor cell division through fluorouracil and irinotecan while reducing inflammation via COX-2 inhibition.
FOLFIRI chemotherapy combined with celecoxib inhibits tumor cell division through fluorouracil and irinotecan while reducing inflammation via COX-2 inhibition. Used for Colorectal cancer (based on FOLFIRI standard use with celecoxib as adjunctive agent).
At a glance
| Generic name | Folferi and celecoxib |
|---|---|
| Sponsor | Sherief Abd-Elsalam |
| Drug class | Chemotherapy combination with COX-2 inhibitor |
| Target | Topoisomerase I (irinotecan), thymidylate synthase (fluorouracil), COX-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
FOLFIRI is a combination chemotherapy regimen (fluorouracil, leucovorin, and irinotecan) that damages DNA and inhibits topoisomerase I in rapidly dividing cancer cells. Celecoxib is a selective COX-2 inhibitor that reduces prostaglandin production, potentially decreasing inflammation and angiogenesis in tumors. The combination aims to enhance anti-tumor efficacy through dual mechanisms.
Approved indications
- Colorectal cancer (based on FOLFIRI standard use with celecoxib as adjunctive agent)
Common side effects
- Neutropenia
- Diarrhea
- Nausea and vomiting
- Fatigue
- Abdominal pain
- Cardiovascular events (celecoxib-related)
Key clinical trials
- Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Folferi and celecoxib CI brief — competitive landscape report
- Folferi and celecoxib updates RSS · CI watch RSS
- Sherief Abd-Elsalam portfolio CI